COVID-19
Conditions
Keywords
COVID-19, METABOLIC DISORDERS, Respiratory function of the lungs
Brief summary
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection. An observational prospective study included 105 patients with a severe course of novel coronavirus infection
Interventions
the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
Ringer's solution at an average daily dose of 8.1 ml/kg/day
Sponsors
Study design
Eligibility
Inclusion criteria
1. age 18-70 years; 2. diagnosis of SARS-COV-2 NCI confirmed by laboratory tests; 3. the lung lesion volume on CT scan is significant or subtotal - CT 3-4; 4. initiation of infusion therapy on the 1st day after patient admission to ICU
Exclusion criteria
* 1\) presence of initial indications for transfer to invasive ALV at the time of screening; 2) history of Reamberin intolerance; 3) administration of other polyelectrolyte solutions with reserve alkalinity carriers; 4) pregnancy and postpartum; 5) severe renal failure requiring renal replacement therapy; 6) severe hepatic failure (Child-Pugh class C or higher); 7) diabetes mellitus; 8) terminal stage of other chronic incurable diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality, % | from date of treatment start until the date of death or the date of discharge from hospital | Proportion of patients died during the period of hospital stay |
| Duration of treatment at ICU, days | from date of treatment start until the date of death or the date of discharge from hospital | Duration of treatment at ICU |
| Duration of treatment after ICU, days | from date of treatment start until the date of death or the date of discharge from hospital | Duration of treatment after ICU |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BE | baseline, day 2, day 3, day 5, day 11 | Blood gases |
| Glucose | baseline, day 2, day 3, day 5, day 11 | Venous blood Glucose |
| Total duration of inpatient treatment, days | from date of treatment start until the date of death or the date of discharge from hospital | Total duration of inpatient treatment |
| Dynamics of right diaphragm excursion, cm | baseline, day 2, day 3, day 5, day 11 | Diaphragm mobility |
| Lactate | baseline, day 2, day 3, day 5, day 11 | Venous blood Lactate |
| pH | baseline, day 2, day 3, day 5, day 11 | Blood gases |
Countries
Russia